{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T04:40:23Z","timestamp":1766983223809,"version":"3.44.0"},"reference-count":44,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2019,6,25]]},"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Precision medicine therapy is remodelling the diagnostic landscape of cancer. The success of these new therapies is often based on the presence or absence of a specific mutation in a tumour. The Idylla platform is designed to determine the mutational status of a tumour as quickly and accurately as possible, as a rapid, accurate diagnosis is of the utmost importance for the treatment of patients. This is the first complete prospective study to investigate the robustness of the Idylla platform for <jats:italic>EGFR<\/jats:italic>, <jats:italic>KRAS<\/jats:italic> and <jats:italic>BRAF<\/jats:italic> mutations in non-small cell lung cancer, metastatic colorectal cancer and metastatic melanoma, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We compared prospectively the Idylla platform with the results we obtained from parallel high-throughput next-generation sequencing, which is the current gold standard for mutational testing. Furthermore, we evaluated the benefits and disadvantages of the Idylla platform in clinical practice. Additionally, we reviewed all the published Idylla performance articles.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There was an overall agreement of 100%, 94% and 94% between the next-generation panel and the Idylla <jats:italic>BRAF<\/jats:italic>, <jats:italic>KRAS<\/jats:italic> and <jats:italic>EGFR<\/jats:italic> mutation test. Two interesting discordant findings among 48 cases were observed and will be discussed together with the advantages and shortcoming of both techniques.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our observations demonstrate that the Idylla cartridge for the <jats:italic>EGFR<\/jats:italic>, <jats:italic>KRAS<\/jats:italic> and <jats:italic>BRAF<\/jats:italic> mutations is highly accurate, rapid and has a limited hands-on time compared with next-generation sequencing.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jclinpath-2019-205970","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T11:15:13Z","timestamp":1562843713000},"page":"35-41","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":29,"title":["Rapid clinical mutational testing of <i>KRAS<\/i>, <i>BRAF<\/i> and <i>EGFR<\/i>: a prospective comparative analysis of the Idylla technique with high-throughput next-generation sequencing"],"prefix":"10.1136","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1064-5809","authenticated-orcid":false,"given":"Matthias","family":"Van Haele","sequence":"first","affiliation":[{"name":"Department of Imaging and Pathology, KU Leuven, Leuven, Belgium"},{"name":"Pathology, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Vander Borght","sequence":"additional","affiliation":[{"name":"Pathology, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An","family":"Ceulemans","sequence":"additional","affiliation":[{"name":"Department of Imaging and Pathology, KU Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiel","family":"Wie\u00ebrs","sequence":"additional","affiliation":[{"name":"Department of Imaging and Pathology, KU Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofie","family":"Metsu","sequence":"additional","affiliation":[{"name":"HistoGeneX NV, Edegem, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Sagaert","sequence":"additional","affiliation":[{"name":"Department of Imaging and Pathology, KU Leuven, Leuven, Belgium"},{"name":"Pathology, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"Weynand","sequence":"additional","affiliation":[{"name":"Department of Imaging and Pathology, KU Leuven, Leuven, Belgium"},{"name":"Pathology, University Hospitals Leuven, Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,7,11]]},"reference":[{"key":"2025092504514317000_73.1.35.1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/cgt.2015.39","article-title":"A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance","volume":"22","author":"Dietel","year":"2015","journal-title":"Cancer Gene Ther"},{"key":"2025092504514317000_73.1.35.2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4723"},{"key":"2025092504514317000_73.1.35.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2015.09.004"},{"key":"2025092504514317000_73.1.35.4","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2015-203345"},{"key":"2025092504514317000_73.1.35.5","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0712"},{"key":"2025092504514317000_73.1.35.6","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jmoldx.2015.12.005","article-title":"Multicenter evaluation of a novel automated rapid detection system of BRAF status in formalin-fixed, paraffin-embedded tissues","volume":"18","author":"Schiefer","year":"2016","journal-title":"J Mol Diagn"},{"key":"2025092504514317000_73.1.35.7","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2016-204025"},{"key":"2025092504514317000_73.1.35.8","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2016-203989"},{"key":"2025092504514317000_73.1.35.9","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2016-203696"},{"key":"2025092504514317000_73.1.35.10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163444","article-title":"Multi-center evaluation of the fully automated PCR-based Idylla\u2122 KRAS mutation assay for rapid KRAS mutation status determination on formalin-fixed paraffin-embedded tissue of human colorectal cancer","volume":"11","author":"Solassol","year":"2016","journal-title":"PLoS One"},{"key":"2025092504514317000_73.1.35.11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153576","article-title":"Detection of BRAF mutations using a fully automated platform and comparison with high resolution melting, real-time allele specific amplification, immunohistochemistry and next generation sequencing assays, for patients with metastatic melanoma","volume":"11","author":"Harl\u00e9","year":"2016","journal-title":"PLoS One"},{"key":"2025092504514317000_73.1.35.12","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/CMR.0000000000000421","article-title":"Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, droplet digital PCR, and the Idylla mutation platform","volume":"28","author":"Bisschop","year":"2018","journal-title":"Melanoma Res"},{"key":"2025092504514317000_73.1.35.13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2340\/00015555-2738","article-title":"Evaluation of a rapid, fully automated platform for detection of BRAF and NRAS mutations in melanoma","volume":"98","author":"Barel","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"2025092504514317000_73.1.35.14","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2017-204629"},{"key":"2025092504514317000_73.1.35.15","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2017-204356"},{"key":"2025092504514317000_73.1.35.16","doi-asserted-by":"crossref","first-page":"103055","DOI":"10.18632\/oncotarget.21476","article-title":"Optimization of EGFR mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer","volume":"8","author":"Ilie","year":"2017","journal-title":"Oncotarget"},{"key":"2025092504514317000_73.1.35.17","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2016-204202"},{"key":"2025092504514317000_73.1.35.18","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.prp.2017.03.011","article-title":"EGFR and KRAS molecular genotyping for pulmonary carcinomas: feasibility of a simple and rapid technique implementable in any department of pathology","volume":"213","author":"Thomas De Montpr\u00e9ville","year":"2017","journal-title":"Pathol Res Pract"},{"key":"2025092504514317000_73.1.35.19","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-017-3112-0","article-title":"Clinical performance evaluation of a sensitive, rapid low-throughput test for KRAS mutation analysis using formalin-fixed, paraffin-embedded tissue samples","volume":"17","author":"Weyn","year":"2017","journal-title":"BMC Cancer"},{"key":"2025092504514317000_73.1.35.20","doi-asserted-by":"crossref","DOI":"10.4103\/1742-6413.200936","article-title":"KRAS detection on archival cytological smears by the novel fully automated polymerase chain reaction-based Idylla mutation test","volume":"14","author":"De Luca","year":"2017","journal-title":"Cytojournal"},{"key":"2025092504514317000_73.1.35.21","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000235","article-title":"Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice","volume":"2","author":"Sherwood","year":"2017","journal-title":"ESMO Open"},{"key":"2025092504514317000_73.1.35.22","doi-asserted-by":"crossref","first-page":"32232","DOI":"10.1158\/1538-7445.AM2017-2719","article-title":"Accelerated BRAF mutation analysis using a fully automated PCR platform improves the management of patients with metastatic melanoma: MELFAST trial","volume":"77","author":"Harle","year":"2017","journal-title":"Cancer Research"},{"key":"2025092504514317000_73.1.35.23","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jmoldx.2018.05.008","article-title":"Multicenter evaluation of the Idylla NRAS-BRAF mutation test in metastatic colorectal cancer","volume":"20","author":"Prieto-Potin","year":"2018","journal-title":"J Mol Diagn"},{"key":"2025092504514317000_73.1.35.24","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2018-205197"},{"key":"2025092504514317000_73.1.35.25","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.21037\/jtd.2018.06.157","article-title":"Endobronchial ultrasound-guided fine-needle aspiration for pulmonary carcinomas genotyping: experience with 398 cases including rapid EGFR\/KRAS analysis in 43 cases","volume":"10","author":"Ghigna","year":"2018","journal-title":"J Thorac Dis"},{"key":"2025092504514317000_73.1.35.26","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21208"},{"key":"2025092504514317000_73.1.35.27","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/bjc.2015.356","article-title":"Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis","volume":"113","author":"Kuan","year":"2015","journal-title":"Br J Cancer"},{"key":"2025092504514317000_73.1.35.28","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jtho.2016.05.008","article-title":"The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016","volume":"11","author":"Tan","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2025092504514317000_73.1.35.29","first-page":"2892","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha","year":"2015","journal-title":"Am J Cancer Res"},{"key":"2025092504514317000_73.1.35.30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2361"},{"key":"2025092504514317000_73.1.35.31","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-1206"},{"key":"2025092504514317000_73.1.35.32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.037"},{"key":"2025092504514317000_73.1.35.33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.5956"},{"key":"2025092504514317000_73.1.35.34","first-page":"5171","article-title":"KRAS mutation testing in metastatic colorectal cancer","volume":"18","author":"Tan","year":"2012","journal-title":"World J Gastroenterol"},{"key":"2025092504514317000_73.1.35.35","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw235"},{"key":"2025092504514317000_73.1.35.36","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1200\/JCO.2016.71.9807","article-title":"Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology","volume":"35","author":"Sepulveda","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025092504514317000_73.1.35.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.10.016"},{"key":"2025092504514317000_73.1.35.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.03.034"},{"key":"2025092504514317000_73.1.35.39","first-page":"2725","article-title":"Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma","volume":"9","author":"Banzi","year":"2016","journal-title":"Onco Targets Ther"},{"key":"2025092504514317000_73.1.35.40","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp698"},{"key":"2025092504514317000_73.1.35.41","doi-asserted-by":"publisher","DOI":"10.1101\/gr.107524.110"},{"key":"2025092504514317000_73.1.35.42","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkq603","article-title":"ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data","volume":"38","author":"Wang","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"2025092504514317000_73.1.35.43","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2017-204579"},{"key":"2025092504514317000_73.1.35.44","doi-asserted-by":"publisher","DOI":"10.1159\/000339534"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2019-205970","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T11:51:49Z","timestamp":1758801109000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2019-205970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,11]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12,12]]},"published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1136\/jclinpath-2019-205970"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2019-205970","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"type":"print","value":"0021-9746"},{"type":"electronic","value":"1472-4146"}],"subject":[],"published":{"date-parts":[[2019,7,11]]}}}